Sublingual specific immunotherapy reduces PBMC proliferations

D. Fenoglio, F. Puppo, I. Cirillo, A. Vizzaccaro, A. Ferrera, M. A. Tosca, G. Marseglia, G. Ciprandi

Research output: Contribution to journalArticlepeer-review


Background: Subcutaneous specific immunotherapy has been demonstrated capable of inducing T regulatory response. There is few evidence concerning immunological changes induced by sublingual immunotherapy. Objective: The aim of this study was to evaluate T cell proliferation in subjects successfully treated with SLIT for HDM. Methods: PBMCs were isolated from patients after at least 3 years of successful HDM SLIT and from matched untreated allergic and healthy control subjects. After 3 and 6 days of in vitro stimulation with PHA, Candida albicans, Dermatophagoides farinae, grasses, Parietaria judaica, and cat, proliferation. Results: Subjects treated with SLIT showed significant reduction of proliferation induced by Candida albicans, Parietaria, and grasses in comparison with untreated atopics (p=0.0002, 0.0033, and 0.009 respectively). Conclusion: This pilot study confirms reduced T cell proliferation in allergic subjects treated with SLIT.

Original languageEnglish
Pages (from-to)147-151
Number of pages5
JournalEuropean Annals of Allergy and Clinical Immunology
Issue number4
Publication statusPublished - Apr 2005


  • Immunologic tolerance
  • Sublingual immunotherapy
  • T cell proliferation

ASJC Scopus subject areas

  • Immunology and Allergy


Dive into the research topics of 'Sublingual specific immunotherapy reduces PBMC proliferations'. Together they form a unique fingerprint.

Cite this